Indeed, significant associations with poor outcomes were found in BCAR1 expressing right-sided, stage I/II, MSS, or BRAF-mutated CRC, indicating that these subgroups might benefit from p130Cas inhibition. The gene discussed is BRAF; the disease is colorectal carcinoma.